Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Daewoong Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	204,262	102,950	111,506	102,951	75,907	72,299
Short-Term Investments	-	5,077	3,000	10,000	97,827	104,821
Trading Asset Securities	4,358	8,320	23,179	27,700	-	-
Cash & Short-Term Investments	208,620	116,347	137,685	140,651	173,734	177,120
Cash Growth	94.05%	-15.50%	-2.11%	-19.04%	-1.91%	36.42%
Accounts Receivable	172,078	160,742	137,506	142,165	121,591	118,355
Other Receivables	45,503	51,150	40,386	36,979	36,916	29,222
Receivables	217,582	211,894	177,892	179,144	159,508	147,578
Inventory	312,356	256,353	241,545	208,736	170,559	173,971
Prepaid Expenses	-	15,950	8,534	7,598	6,604	8,214
Other Current Assets	50,949	12,248	9,168	12,840	9,996	21,469
Total Current Assets	789,507	612,792	574,824	548,968	520,401	528,351
Property, Plant & Equipment	762,918	675,666	521,919	440,890	395,866	393,690
Long-Term Investments	169,560	180,703	203,792	146,335	118,369	144,876
Goodwill	-	60,848	60,848	60,848	60,848	60,848
Other Intangible Assets	371,201	83,042	80,001	84,620	81,406	73,106
Long-Term Accounts Receivable	-	-	-	-	569.7	522.85
Long-Term Deferred Tax Assets	81,953	68,786	71,304	64,136	58,565	32,572
Long-Term Deferred Charges	-	202,820	156,636	120,540	82,915	44,788
Other Long-Term Assets	81,695	88,613	97,660	93,745	91,747	87,153
Total Assets	2,260,504	1,976,977	1,770,311	1,563,341	1,410,687	1,366,908
Accounts Payable	109,779	83,043	101,099	83,401	70,852	78,785
Accrued Expenses	8,824	24,010	24,085	20,635	15,485	14,986
Short-Term Debt	103,421	206,495	167,426	141,742	56,109	57,053
Current Portion of Long-Term Debt	205,898	115,000	204,943	91,931	199,878	89,926
Current Portion of Leases	1,209	2,002	1,961	1,183	987.32	984.16
Current Income Taxes Payable	21,043	8,146	14,497	4,906	4,734	2,660
Current Unearned Revenue	113.55	76.15	59.22	30.67	-	-
Other Current Liabilities	198,543	155,573	153,047	129,004	112,615	82,356
Total Current Liabilities	648,830	594,346	667,117	472,831	460,660	326,750
Long-Term Debt	481,490	324,478	65,000	204,840	181,713	291,165
Long-Term Leases	991.53	1,274	1,941	7,015	7,008	6,562
Pension & Post-Retirement Benefits	2,659	722.46	-	-	-	-
Long-Term Deferred Tax Liabilities	3,499	3,530	5,009	4,053	3,580	4,146
Other Long-Term Liabilities	83,837	90,573	90,547	133,378	59,811	43,035
Total Liabilities	1,221,306	1,014,923	829,614	822,118	712,772	671,659
Common Stock	28,966	28,966	28,966	28,966	28,966	28,966
Additional Paid-In Capital	149,195	149,892	149,175	121,582	123,649	101,097
Retained Earnings	734,737	635,674	618,864	504,294	467,361	452,802
Treasury Stock	-2,850	-2,850	-2,850	-18,360	-18,360	-29,236
Comprehensive Income & Other	-30,195	-17,044	-26,852	-28,466	-32,085	-2,635
Total Common Equity	879,854	794,640	767,303	608,017	569,531	550,994
Minority Interest	124,274	132,345	144,978	133,206	128,384	144,255
Shareholders' Equity	1,039,197	962,055	940,696	741,223	697,915	695,249
Total Liabilities & Equity	2,260,504	1,976,977	1,770,311	1,563,341	1,410,687	1,366,908
Total Debt	793,009	649,249	441,270	446,711	445,695	445,690
Net Cash (Debt)	-584,390	-532,902	-303,585	-306,060	-271,961	-268,570
Net Cash Per Share	-50786.95	-46314.03	-26572.35	-27649.69	-24713.54	-25188.32
Filing Date Shares Outstanding	11.51	11.51	11.51	11.07	11.07	10.76
Total Common Shares Outstanding	11.51	11.51	11.51	11.07	11.07	10.76
Working Capital	140,677	18,447	-92,293	76,137	59,742	201,601
Book Value Per Share	76475.31	69061.46	66685.66	54928.72	51451.87	51194.76
Tangible Book Value	508,653	650,750	626,454	462,550	427,278	417,039
Tangible Book Value Per Share	44211.21	56556.09	54444.60	41787.05	38600.56	38748.60
Land	-	83,840	97,598	94,459	69,482	66,814
Buildings	-	296,280	267,669	261,085	247,556	244,998
Machinery	-	360,301	340,864	325,145	307,618	304,899
Construction In Progress	-	267,131	131,731	58,328	47,216	32,046

Source: S&P Global Market Intelligence. Standard template. Financial Sources.